US EditionStudy Examines Potential Impact of the Medicare Prescription Payment Plan on Cancer Patients
Nearly half of Medicare Part D cancer patients reach their out-of-pocket cap, but low awareness of the 2025 plan limits its use and potential benefits, CMS data show.
2 Articles
2 Articles
Study examines potential impact of the Medicare Prescription Payment Plan on cancer patients
A new study examines the potential impact of the Medicare Prescription Payment Plan (M3P) - an opt-in policy implemented in 2025 under the Inflation Reduction Act that allows beneficiaries to spread out of pocket (OOP) costs over the calendar year - on Medicare Part D beneficiaries with cancer who face high out-of-pocket (OOP) prescription drug costs.
Spreading drug costs over the year may ease financial burden for Medicare cancer patients
A new study examines the potential impact of the Medicare Prescription Payment Plan (M3P)—an opt-in policy implemented in 2025 under the Inflation Reduction Act that allows beneficiaries to spread out-of-pocket (OOP) costs over the calendar year—on Medicare Part D beneficiaries with cancer who face high out-of-pocket (OOP) prescription drug costs.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
